5 Stocks with Biggest Upside Potential According to Analysts

In this article, we will take a look at the 5 stocks with biggest upside potential according to analysts. To read our analysis of recent market trends, you can go to 12 Stocks with Biggest Upside Potential According to Analysts.

5. Arvinas, Inc. (NASDAQ:ARVN)

Number of Hedge Fund Holders: 22

Upside Potential as of July 20: 188.63%

New Haven, Connecticut-based Arvinas, Inc. (NASDAQ:ARVN) is a clinical-stage biopharmaceutical company focused on the development of therapies that degrade disease-causing proteins. It uses its proprietary PROTAC® Discovery Engine platform to engineer targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins selectively and efficiently.

The clinical stage programs of Arvinas, Inc. (NASDAQ:ARVN) include bavdegalutamide (ARV-110) and ARV-766 for the treatment of men with prostate cancer, and vepdegestrant (ARV-471) for the treatment of patients with breast cancer.

On July 6, Carrick Therapeutics Ltd announced a clinical trial collaboration and supply agreement with Arvinas, Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE). The agreement covers the execution of a Phase 1b/2 clinical trial to evaluate the combination of Carrick’s samuraciclib (CT7001) and Arvinas’ vepdegestrant for the treatment of advanced breast cancer.

On June 26, Oppenheimer analyst Matthew Biegler assumed coverage of Arvinas, Inc. (NASDAQ:ARVN) shares with an ‘Outperform’ rating and a target price of $95.0 per share. The target price represents a potential upside of 291.43% based on the share price on July 20.